Study to Assess Safety, Tolerability and Efficacy of SC Administered MBL949 in Obese Participants With or Without T2DM
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05199090 |
Recruitment Status :
Completed
First Posted : January 20, 2022
Last Update Posted : August 22, 2023
|
Sponsor:
Novartis Pharmaceuticals
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )
- Study Details
- Tabular View
- Results Submitted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : | Completed |
---|---|
Actual Primary Completion Date : | May 11, 2023 |
Actual Study Completion Date : | May 11, 2023 |
Submission Cycle | Results Submitted to ClinicalTrials.gov | Results Returned after Quality Control Review |
---|---|---|
1 |
May 3, 2024 |